nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGS2—atherosclerosis	0.754	1	CbGaD
Tafluprost—Common cold—Pravastatin—atherosclerosis	0.00777	0.149	CcSEcCtD
Tafluprost—Iloprost—PLAT—atherosclerosis	0.00724	1	CrCbGaD
Tafluprost—PTGS2—leg—atherosclerosis	0.00545	0.172	CbGeAlD
Tafluprost—PTGS2—hindlimb—atherosclerosis	0.00487	0.153	CbGeAlD
Tafluprost—Endophthalmitis—Pravastatin—atherosclerosis	0.00426	0.0816	CcSEcCtD
Tafluprost—PTGS2—appendage—atherosclerosis	0.00418	0.131	CbGeAlD
Tafluprost—PTGFR—adipose tissue—atherosclerosis	0.00333	0.105	CbGeAlD
Tafluprost—PTGS2—artery—atherosclerosis	0.00299	0.0939	CbGeAlD
Tafluprost—Eye irritation—Lovastatin—atherosclerosis	0.00281	0.0538	CcSEcCtD
Tafluprost—PTGS2—endothelium—atherosclerosis	0.00252	0.0794	CbGeAlD
Tafluprost—Cataract—Lovastatin—atherosclerosis	0.00252	0.0483	CcSEcCtD
Tafluprost—Cataract—Simvastatin—atherosclerosis	0.00236	0.0452	CcSEcCtD
Tafluprost—PTGFR—liver—atherosclerosis	0.00234	0.0735	CbGeAlD
Tafluprost—PTGS2—blood vessel—atherosclerosis	0.00233	0.0732	CbGeAlD
Tafluprost—Cataract—Pravastatin—atherosclerosis	0.00213	0.0408	CcSEcCtD
Tafluprost—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00154	0.0295	CcSEcCtD
Tafluprost—Nasopharyngitis—Ezetimibe—atherosclerosis	0.00153	0.0293	CcSEcCtD
Tafluprost—Rhinitis—Rosuvastatin—atherosclerosis	0.00142	0.0273	CcSEcCtD
Tafluprost—Nasopharyngitis—Pravastatin—atherosclerosis	0.00132	0.0252	CcSEcCtD
Tafluprost—Urinary tract infection—Lovastatin—atherosclerosis	0.0013	0.025	CcSEcCtD
Tafluprost—PTGS2—connective tissue—atherosclerosis	0.00119	0.0375	CbGeAlD
Tafluprost—Urinary tract infection—Pravastatin—atherosclerosis	0.0011	0.0211	CcSEcCtD
Tafluprost—Cough—Rosuvastatin—atherosclerosis	0.00108	0.0207	CcSEcCtD
Tafluprost—PTGS2—cardiovascular system—atherosclerosis	0.00104	0.0326	CbGeAlD
Tafluprost—Rhinitis—Niacin—atherosclerosis	0.00104	0.0199	CcSEcCtD
Tafluprost—Rhinitis—Pravastatin—atherosclerosis	0.00102	0.0196	CcSEcCtD
Tafluprost—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00099	0.019	CcSEcCtD
Tafluprost—Vision blurred—Lovastatin—atherosclerosis	0.000988	0.0189	CcSEcCtD
Tafluprost—Eye disorder—Niacin—atherosclerosis	0.000966	0.0185	CcSEcCtD
Tafluprost—Vision blurred—Simvastatin—atherosclerosis	0.000924	0.0177	CcSEcCtD
Tafluprost—PTGS2—adipose tissue—atherosclerosis	0.000915	0.0288	CbGeAlD
Tafluprost—Cough—Ezetimibe—atherosclerosis	0.000897	0.0172	CcSEcCtD
Tafluprost—Vision blurred—Niacin—atherosclerosis	0.000848	0.0163	CcSEcCtD
Tafluprost—Vision blurred—Pravastatin—atherosclerosis	0.000835	0.016	CcSEcCtD
Tafluprost—Nervous system disorder—Ezetimibe—atherosclerosis	0.000823	0.0158	CcSEcCtD
Tafluprost—Cough—Niacin—atherosclerosis	0.000786	0.0151	CcSEcCtD
Tafluprost—Cough—Pravastatin—atherosclerosis	0.000773	0.0148	CcSEcCtD
Tafluprost—Dyspnoea—Lovastatin—atherosclerosis	0.000763	0.0146	CcSEcCtD
Tafluprost—Dyspnoea—Ezetimibe—atherosclerosis	0.000748	0.0143	CcSEcCtD
Tafluprost—Pruritus—Rosuvastatin—atherosclerosis	0.000714	0.0137	CcSEcCtD
Tafluprost—Dyspnoea—Simvastatin—atherosclerosis	0.000713	0.0137	CcSEcCtD
Tafluprost—Dyspnoea—Niacin—atherosclerosis	0.000655	0.0126	CcSEcCtD
Tafluprost—Dyspnoea—Pravastatin—atherosclerosis	0.000645	0.0124	CcSEcCtD
Tafluprost—PTGS2—liver—atherosclerosis	0.000642	0.0202	CbGeAlD
Tafluprost—Headache—Rosuvastatin—atherosclerosis	0.000632	0.0121	CcSEcCtD
Tafluprost—Pruritus—Lovastatin—atherosclerosis	0.000605	0.0116	CcSEcCtD
Tafluprost—Pruritus—Ezetimibe—atherosclerosis	0.000594	0.0114	CcSEcCtD
Tafluprost—Pruritus—Simvastatin—atherosclerosis	0.000566	0.0109	CcSEcCtD
Tafluprost—Headache—Lovastatin—atherosclerosis	0.000536	0.0103	CcSEcCtD
Tafluprost—Headache—Ezetimibe—atherosclerosis	0.000526	0.0101	CcSEcCtD
Tafluprost—Pruritus—Niacin—atherosclerosis	0.00052	0.00997	CcSEcCtD
Tafluprost—Pruritus—Pravastatin—atherosclerosis	0.000512	0.00981	CcSEcCtD
Tafluprost—Headache—Simvastatin—atherosclerosis	0.000501	0.00961	CcSEcCtD
Tafluprost—Headache—Niacin—atherosclerosis	0.00046	0.00882	CcSEcCtD
Tafluprost—Headache—Pravastatin—atherosclerosis	0.000453	0.00869	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—CASR—atherosclerosis	0.00029	0.00187	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—CRP—atherosclerosis	0.000289	0.00187	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CX3CL1—atherosclerosis	0.000284	0.00184	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—atherosclerosis	0.000283	0.00183	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—APOA1—atherosclerosis	0.00028	0.00181	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HRH1—atherosclerosis	0.000277	0.00179	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CNR2—atherosclerosis	0.00027	0.00174	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—F2—atherosclerosis	0.000267	0.00172	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—ICAM1—atherosclerosis	0.000266	0.00172	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000264	0.00171	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ABCG8—atherosclerosis	0.000261	0.00169	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—LTA4H—atherosclerosis	0.000261	0.00169	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—atherosclerosis	0.000257	0.00166	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—AGT—atherosclerosis	0.000244	0.00158	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—INS—atherosclerosis	0.000242	0.00156	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—atherosclerosis	0.00024	0.00155	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—CCL2—atherosclerosis	0.000238	0.00154	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCL3—atherosclerosis	0.000232	0.0015	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCR2—atherosclerosis	0.000231	0.00149	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—EDNRA—atherosclerosis	0.000231	0.00149	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—F2—atherosclerosis	0.000226	0.00146	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—GHRL—atherosclerosis	0.000225	0.00145	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—LEP—atherosclerosis	0.000224	0.00145	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—SERPINE1—atherosclerosis	0.000222	0.00143	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—ALB—atherosclerosis	0.000222	0.00143	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—TNF—atherosclerosis	0.00022	0.00142	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TLR4—atherosclerosis	0.000219	0.00142	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APOA4—atherosclerosis	0.000218	0.0014	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	0.000217	0.0014	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—ICAM1—atherosclerosis	0.00021	0.00136	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCR2—atherosclerosis	0.00021	0.00135	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—EDNRA—atherosclerosis	0.00021	0.00135	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000209	0.00135	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—NOS2—atherosclerosis	0.000209	0.00135	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ABCG1—atherosclerosis	0.000207	0.00133	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—atherosclerosis	0.000206	0.00133	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—GHRL—atherosclerosis	0.000204	0.00132	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IFNG—atherosclerosis	0.000202	0.00131	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCL2—atherosclerosis	0.000201	0.0013	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL4—atherosclerosis	0.0002	0.00129	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—KNG1—atherosclerosis	0.000197	0.00127	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AGTR1—atherosclerosis	0.000196	0.00127	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—LCAT—atherosclerosis	0.000194	0.00125	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—FABP4—atherosclerosis	0.000194	0.00125	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—SIRT1—atherosclerosis	0.000193	0.00125	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—APOA4—atherosclerosis	0.000191	0.00123	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CCL2—atherosclerosis	0.000188	0.00122	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP7A1—atherosclerosis	0.000187	0.00121	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APOA2—atherosclerosis	0.000187	0.00121	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL1B—atherosclerosis	0.000181	0.00117	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—KNG1—atherosclerosis	0.000179	0.00116	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—UTS2—atherosclerosis	0.000179	0.00115	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AGTR1—atherosclerosis	0.000178	0.00115	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP27A1—atherosclerosis	0.000173	0.00112	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—atherosclerosis	0.000172	0.00111	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CX3CR1—atherosclerosis	0.000171	0.00111	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CASR—atherosclerosis	0.000171	0.00111	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—NFKB1—atherosclerosis	0.000168	0.00109	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CX3CL1—atherosclerosis	0.000168	0.00108	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—EDN1—atherosclerosis	0.000166	0.00107	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCL5—atherosclerosis	0.000165	0.00107	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—APOA2—atherosclerosis	0.000164	0.00106	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PLA2G2A—atherosclerosis	0.000164	0.00106	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ALOX5AP—atherosclerosis	0.000164	0.00106	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—atherosclerosis	0.000164	0.00106	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ABCG5—atherosclerosis	0.000162	0.00105	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IFNG—atherosclerosis	0.00016	0.00103	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CNR2—atherosclerosis	0.000159	0.00103	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCL8—atherosclerosis	0.000159	0.00103	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—MMP3—atherosclerosis	0.000159	0.00103	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	0.000159	0.00102	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PRKCG—atherosclerosis	0.000157	0.00101	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—LPA—atherosclerosis	0.000157	0.00101	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—EDN1—atherosclerosis	0.000151	0.000976	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	0.00015	0.000969	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCL5—atherosclerosis	0.00015	0.000968	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CXCL8—atherosclerosis	0.000149	0.000961	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—atherosclerosis	0.000145	0.000939	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	0.000144	0.000933	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL1B—atherosclerosis	0.000143	0.000922	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LDLRAP1—atherosclerosis	0.000143	0.000922	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PRKCG—atherosclerosis	0.000143	0.00092	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—VWF—atherosclerosis	0.000142	0.000916	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APOC3—atherosclerosis	0.000141	0.000911	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LDLR—atherosclerosis	0.00014	0.000905	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	0.00014	0.000901	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AGT—atherosclerosis	0.000138	0.000892	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL3—atherosclerosis	0.000137	0.000884	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MMP9—atherosclerosis	0.000135	0.000869	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PLTP—atherosclerosis	0.000134	0.000867	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NCF1—atherosclerosis	0.000131	0.000847	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—TNF—atherosclerosis	0.000131	0.000846	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—F2—atherosclerosis	0.000128	0.000824	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—atherosclerosis	0.000126	0.000813	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AGT—atherosclerosis	0.000125	0.00081	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	0.000124	0.000803	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EDNRA—atherosclerosis	0.000124	0.000799	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCR2—atherosclerosis	0.000124	0.000799	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	0.000124	0.000798	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CYBA—atherosclerosis	0.000123	0.000796	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	0.000123	0.000793	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000122	0.000789	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GHRL—atherosclerosis	0.000121	0.000779	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PLAT—atherosclerosis	0.000121	0.000779	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PARP1—atherosclerosis	0.000121	0.000779	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	0.00012	0.000775	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LTA4H—atherosclerosis	0.000116	0.000751	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ABCG8—atherosclerosis	0.000116	0.000751	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—F2—atherosclerosis	0.000116	0.000748	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	0.000115	0.000742	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MAPK3—atherosclerosis	0.000114	0.000738	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TGFB1—atherosclerosis	0.000111	0.000716	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CG—atherosclerosis	0.000111	0.000716	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	0.000109	0.000701	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KNG1—atherosclerosis	0.000106	0.000684	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL6—atherosclerosis	0.000106	0.000683	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AGTR1—atherosclerosis	0.000105	0.00068	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TNF—atherosclerosis	0.000104	0.000669	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCL2—atherosclerosis	0.000103	0.000667	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PLG—atherosclerosis	0.000103	0.000662	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APOA4—atherosclerosis	0.000101	0.000655	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SOCS3—atherosclerosis	9.72e-05	0.000627	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	9.67e-05	0.000624	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MMP3—atherosclerosis	9.38e-05	0.000606	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IGF2—atherosclerosis	9.34e-05	0.000603	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ABCG1—atherosclerosis	9.2e-05	0.000594	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APOB—atherosclerosis	9.07e-05	0.000586	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	9.06e-05	0.000585	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CXCL8—atherosclerosis	8.99e-05	0.000581	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EDN1—atherosclerosis	8.93e-05	0.000576	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	8.91e-05	0.000575	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL5—atherosclerosis	8.86e-05	0.000572	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APOA2—atherosclerosis	8.73e-05	0.000563	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LPL—atherosclerosis	8.66e-05	0.000559	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—FABP4—atherosclerosis	8.65e-05	0.000558	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LCAT—atherosclerosis	8.65e-05	0.000558	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—APOA4—atherosclerosis	8.49e-05	0.000548	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PRKCG—atherosclerosis	8.42e-05	0.000544	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL6—atherosclerosis	8.36e-05	0.00054	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP7A1—atherosclerosis	8.34e-05	0.000538	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	8.22e-05	0.000531	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SPP1—atherosclerosis	8.2e-05	0.00053	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCL8—atherosclerosis	8.17e-05	0.000527	CbGpPWpGaD
Tafluprost—PTGS2—Disease—BGN—atherosclerosis	8.06e-05	0.000521	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	7.95e-05	0.000513	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	7.78e-05	0.000502	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP27A1—atherosclerosis	7.71e-05	0.000498	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PDGFB—atherosclerosis	7.59e-05	0.00049	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	7.59e-05	0.00049	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	7.55e-05	0.000487	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AGT—atherosclerosis	7.41e-05	0.000478	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	7.4e-05	0.000478	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALOX15—atherosclerosis	7.31e-05	0.000472	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—APOA2—atherosclerosis	7.31e-05	0.000472	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALOX5AP—atherosclerosis	7.31e-05	0.000472	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PLA2G2A—atherosclerosis	7.31e-05	0.000472	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LEP—atherosclerosis	7.26e-05	0.000469	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APOE—atherosclerosis	7.26e-05	0.000469	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ABCG5—atherosclerosis	7.22e-05	0.000466	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	7.21e-05	0.000466	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CAV1—atherosclerosis	7.19e-05	0.000464	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APOA1—atherosclerosis	7.18e-05	0.000463	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	7.05e-05	0.000455	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CST3—atherosclerosis	7.03e-05	0.000454	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LPA—atherosclerosis	6.97e-05	0.00045	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ESR1—atherosclerosis	6.93e-05	0.000447	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—F2—atherosclerosis	6.85e-05	0.000442	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—BGN—atherosclerosis	6.75e-05	0.000436	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	6.7e-05	0.000433	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—APOA5—atherosclerosis	6.68e-05	0.000432	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NAMPT—atherosclerosis	6.66e-05	0.00043	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APOC3—atherosclerosis	6.57e-05	0.000424	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CG—atherosclerosis	6.55e-05	0.000423	CbGpPWpGaD
Tafluprost—PTGS2—Disease—LDLR—atherosclerosis	6.53e-05	0.000422	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	6.49e-05	0.000419	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PLA2G1B—atherosclerosis	6.43e-05	0.000415	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	6.36e-05	0.000411	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HSPA1B—atherosclerosis	6.31e-05	0.000407	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	6.3e-05	0.000407	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	6.29e-05	0.000406	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—MAPK3—atherosclerosis	6.27e-05	0.000405	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALOX5—atherosclerosis	6.21e-05	0.000401	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—INS—atherosclerosis	6.2e-05	0.0004	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NCF1—atherosclerosis	6.11e-05	0.000395	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL2—atherosclerosis	6.1e-05	0.000394	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IGF1—atherosclerosis	6e-05	0.000387	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CYBA—atherosclerosis	5.74e-05	0.000371	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	5.74e-05	0.000371	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SERPINE1—atherosclerosis	5.7e-05	0.000368	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PARP1—atherosclerosis	5.62e-05	0.000363	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NAMPT—atherosclerosis	5.57e-05	0.00036	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	5.54e-05	0.000358	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LIPC—atherosclerosis	5.54e-05	0.000358	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—APOC3—atherosclerosis	5.5e-05	0.000355	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LDLR—atherosclerosis	5.47e-05	0.000353	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOS3—atherosclerosis	5.44e-05	0.000351	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CETP—atherosclerosis	5.34e-05	0.000345	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	5.25e-05	0.000339	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SCARB1—atherosclerosis	5.12e-05	0.00033	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	4.98e-05	0.000322	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HMGCR—atherosclerosis	4.83e-05	0.000312	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCL8—atherosclerosis	4.82e-05	0.000311	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AKT1—atherosclerosis	4.66e-05	0.000301	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6—atherosclerosis	4.59e-05	0.000296	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MMP9—atherosclerosis	4.36e-05	0.000282	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NFKB1—atherosclerosis	4.32e-05	0.000279	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ABCA1—atherosclerosis	4.31e-05	0.000278	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MAPK8—atherosclerosis	4.24e-05	0.000274	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AKT1—atherosclerosis	4.23e-05	0.000273	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APOB—atherosclerosis	4.23e-05	0.000273	CbGpPWpGaD
Tafluprost—PTGS2—Disease—LPL—atherosclerosis	4.04e-05	0.000261	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PRKCG—atherosclerosis	3.92e-05	0.000253	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—VEGFA—atherosclerosis	3.92e-05	0.000253	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—STAT3—atherosclerosis	3.88e-05	0.00025	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MAPK3—atherosclerosis	3.71e-05	0.000239	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HMOX1—atherosclerosis	3.7e-05	0.000239	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MTHFR—atherosclerosis	3.63e-05	0.000235	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TGFB1—atherosclerosis	3.6e-05	0.000232	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—APOB—atherosclerosis	3.54e-05	0.000229	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PDGFB—atherosclerosis	3.54e-05	0.000228	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTM1—atherosclerosis	3.44e-05	0.000222	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APOE—atherosclerosis	3.38e-05	0.000218	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LPL—atherosclerosis	3.38e-05	0.000218	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CAV1—atherosclerosis	3.35e-05	0.000216	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APOA1—atherosclerosis	3.34e-05	0.000216	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GPX1—atherosclerosis	3.3e-05	0.000213	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CD36—atherosclerosis	3.21e-05	0.000207	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NOS2—atherosclerosis	3.15e-05	0.000204	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—MTHFR—atherosclerosis	3.04e-05	0.000196	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PPARA—atherosclerosis	2.99e-05	0.000193	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AGT—atherosclerosis	2.89e-05	0.000187	CbGpPWpGaD
Tafluprost—PTGS2—Disease—INS—atherosclerosis	2.89e-05	0.000187	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—APOE—atherosclerosis	2.83e-05	0.000183	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CAV1—atherosclerosis	2.81e-05	0.000181	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—APOA1—atherosclerosis	2.8e-05	0.000181	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6—atherosclerosis	2.71e-05	0.000175	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SERPINE1—atherosclerosis	2.65e-05	0.000171	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CG—atherosclerosis	2.56e-05	0.000165	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NOS3—atherosclerosis	2.53e-05	0.000164	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKT1—atherosclerosis	2.5e-05	0.000161	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PPARG—atherosclerosis	2.47e-05	0.000159	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—INS—atherosclerosis	2.42e-05	0.000156	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALB—atherosclerosis	2.22e-05	0.000143	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NOS3—atherosclerosis	2.12e-05	0.000137	CbGpPWpGaD
Tafluprost—PTGS2—Disease—STAT3—atherosclerosis	1.81e-05	0.000117	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MAPK3—atherosclerosis	1.73e-05	0.000112	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TGFB1—atherosclerosis	1.68e-05	0.000108	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6—atherosclerosis	1.26e-05	8.15e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—AKT1—atherosclerosis	1.16e-05	7.52e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AKT1—atherosclerosis	9.76e-06	6.3e-05	CbGpPWpGaD
